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Abstract
Synthetic polymers of a specific shape and size play major role in drug delivery systems. Dendrimers are unique synthetic
macromolecules of nanometer dimensions with a highly branched structure and globular shape with potential applications
in gene and drug delivery. We examine the interaction of several dendrimers of different compositions mPEG-PAMAM (G3),
mPEG-PAMAM (G4) and PAMAM (G4) with hydrophilic and hydrophobic drugs cisplatin, resveratrol, genistein and curcumin
at physiological conditions. FTIR and UV-visible spectroscopic methods as well as molecular modeling were used to analyse
drug binding mode, the binding constant and the effects of drug complexation on dendrimer stability and conformation.
Structural analysis showed that cisplatin binds dendrimers in hydrophilic mode via Pt cation and polymer terminal NH2
groups, while curcumin, genistein and resveratrol are located mainly in the cavities binding through both hydrophobic and
hydrophilic contacts. The overall binding constants of durg-dendrimers are ranging from 10
2 M
21 to 10
3 M
21. The affinity of
dendrimer binding was PAMAM-G4.mPEG-PAMAM-G4.mPEG-PAMAM-G3, while the order of drug-polymer stability was
curcumin.cisplatin.genistein.resveratrol. Molecular modeling showed larger stability for genisten-PAMAM-G4
(DG=24.75 kcal/mol) than curcumin-PAMAM-G4 ((DG=24.53 kcal/mol) and resveratrol-PAMAM-G4 ((DG=24.39 kcal/
mol). Dendrimers might act as carriers to transport hydrophobic and hydrophilic drugs.
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Introduction
The generation of particular systems with a specific shape and
size plays a crucial role in the development of modern drug
delivery systems [1,2]. Dendrimers are unique synthetic macro-
molecules of nanometer dimensions with a highly branched
structure and globular shape [3,4]. Among dendrimers, poly-
amidoamine (PAMAM) (Fig. 1) have received most attention as
potential gene and drug delivery systems [5–8]. Several attempts
have been made to design different dendrimers as drug carriers
[9]. For example, anticancer fluorouracil drug was attached to the
dendrimers with cyclic core [10] or using dendrimers having
poly(ethylene glycol) grafts to encapsulate antitumor drugs
adriamycin and methotrexate [11]. Similarly, it has been shown
that a poly(propylene imine) dendrimer endcapped with 64 L-
phenylalanine encapsulated nearly 4 molecules of Bengal Rose for
every dendritic molecule [12]. Because dendrimers have a large
number of terminal groups to which drug molecules can be
attached, they can carry drug with a high efficiency. They contain
several binding sites for hydrophobic, hydrophilic, cationic and
anionic drugs. Using dendrimers for drug delivery, it is important
to know their biological properties such as toxicity and
biocompatibility. It has been demonstrated that, modification of
the amino groups on the periphery of the dendrimer with
poly(ethylene glycol) chains reduces the toxicity and increases the
biocompatibility of the resulting polymer [13,14]. This is because
poly(ethylene glycol) is nontoxic, nonimmunogenic and water
soluble, and its conjugation with other substrates, produces
conjugates which combine the properties of both the substrate
and the polymer. However, conjugate formation can alter the
binding affinity of PAMAM to DNA or drug in general. In recent
years, major attention has been focused on transporting drug by
dendrimers [15], since these polymers contain several binding
domains for different drugs complexation.
Curcumin (Cur) 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-hep-
tadiens-3,5-dione (Fig. 1) the main yellow pigment of the
powdered rhiome (turmeric) of the herb curcuma longa has been
used for centuries as a spice and food coloring agent [16]. It has
also been used to treat diseases such as inflammation, skin wounds
and tumors as traditional medicine [17]. Curcumin exhibits
antioxidant activity both in vivo and in vitro [17]. Apart from its
anti-inflammatory, antimicrobial and antiviral properties curcu-
min is considered as cancer chemopreventive agent [18,19].
Genistein (Gen) 49,5,7-trihydroxy isoflavone (Fig. 1) presents in
soybean and chick peas has a wide spectrum of physiological and
pharmacological functions. It is known to antagonize human
melanoma cell growth at G2/M transition [20] and found to
inhibit H2O2/Cu(II) mediated DNA strand breaks acting as a
direct scavenger of reactive oxygen species with the OH group at
C-4 position responsible for its antioxidant activity [21].
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33102Figure 1. Chemical structures of PAMAM-G4 dendrimer, cisplatin, curcumin, resveratrol and genistein.
doi:10.1371/journal.pone.0033102.g001
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polyphenolic compound present in variety of dietary plants like
grape, berries and peanuts and has been identified as potential
cardioprotective and chemopreventive agent against chemical
carcinogens [22]. It is known to arrest cell cycle at the transition
phase from S to G2/M in SW480 human colorectal cells [23]. It is
similar structurally to genistein having OH group at C-4 position
with major role in antioxidant activity [21,24].
Cis-dichlrodiamineplatinum(II) (cisPt or cisplatin) (Fig. 1), is an
anticancer drug, which exerts its antitumor activity by binding
DNA via intrastrand cross-links to d(GpG)(dG=deoxyguanosine)
and to d(ApG) (dA=deoxyadenosine), interfering with DNA
replication and transcription and causing cell death [25,26].
Our designed question was to determine if the dendrimers are
capable of complexation with hydrophobic and hydrophilic drugs
and to examine the binding of different drugs with dendrimers in
aqueous solution in order to propose a mechanism of action by
which dendrimres transport drugs in vitro.
In this report, we present spectroscopic and docking results on
the interactions of different drugs curcumin, resveratrol and
genistein (mainly hydrophobic) and cisplatin (hydrophilic) with
several dendrimers of different compositions PAMAM (G4), m-
PEG-PAMAM (G3) and m-PEG-PAMAM (G4) in aqueous
solution at physiological conditions, using constant polymer
concentration and various drugs contents. Structural information
regarding drug hydrophobic and hydrophilic bindings and the
effects of drug complexation on dendrimer stability and confor-
mation in drug-polymer complexes is reported here.
Materials and Methods
Materials
Resveratrol, genistein, curcumin and cisplatin were purchased
from Sigma Chemical Co and used as supplied. PAMAM-G4
(MW 14214 g/mol) was purchased from Aldrich Chemical Co
and used as supplied. mPEG-PAMAM-G3 (MW 13423 g/mol)
and mPEG-PAMAM-G4 (MW 19214 g/mol) (mPEG block has a
molecular weight of 5000 g/mol) were synthesized according to
published methods [9,27]. Other chemicals were of reagent grade
and used without further purification.
Preparation of stock solutions
Solution of dendrimer 1 mM was prepared in distilled water
and diluted to various concentrations in Tris-HCl. Solutions of
curcumin, resveratrol and genistein (1 mM) were prepared in
water/ethanol 50/50%), while cisplatin sample (1 mM) was
prepared in hot water solution. The pH of stock solutions was
kept at 760.2.
FTIR spectroscopy
Infrared spectra were recorded on a FTIR spectrometer (Impact
420 model), equipped with deuterated triglycine sulphate (DTGS)
detector and KBr beam splitter, using AgBr windows. Solution of
drug was added dropwise to the dendrimer solution with constant
stirring to ensure the formation of homogeneous solution and to
reach the target drug concentrations of 0.125, 0.25, and 0.5 mM
with a final dendrimer concentration of 0.5 mM. Spectra were
collected after 2 h incubation of drug and polymer at room
temperature, using hydrated films [28]. Interferograms were
accumulated over the spectral range 4000-600 cm
21 with a
nominal resolution of 4 cm
21 and 100 scans. The difference
spectra [(drug+dendrimer solution) – (dendrimer solution)] were
generated [28].
UV-Visible spectroscopy
The UV-Vis spectra were recorded on a Perkin-Elmer Lambda
spectrophotometer with a slit of 2 nm and scan speed of 400 nm
min
21. Quartz cuvettes of 1 cm were used. The absorbance
assessments were performed at pH 7.0 by keeping the concentra-
tion of dendrimer constant (0.14 mM), while varying the
concentration of the pigment 0.025 mM to 0.0625 mM.
The binding constants were obtained according to the method
described by Connors [29]. It is assumed that the interaction
between the ligand L and the substrate S is 1:1; for this reason a
single complex SL (1:1) is formed. It was also assumed that the sites
(and all the binding sites) are independent and finally the Beer’s
law is followed by all species. A wavelength is selected at which the
molar absorptivities eS (molar absorptivity of the substrate) and e11
(molar absorptivity of the complex) are different. Then at total
concentration St of the substrate, in the absence of ligand and the
light path length is b=1 cm, the solution absorbance is
Ao~eSbSt ð1Þ
In the presence of ligand at total concentration Lt, the absorbance
of a solution containing the same total substrate concentration is
AL~eSbS ½  zeLbL ½  ze11bS L ½  ð 2Þ
(where [S] is the concentration of the uncomplexed substrate, [L]
the concentration of the uncomplexed ligand and [SL] is the
concentration of the complex) which, combined with the mass
balance on S and L, gives
AL~eSbStzeLbLtzDe11bS L ½  ð 3Þ
where De11=e112eS2eL (eL molar absorptivity of the ligand). By
measuring the solution absorbance against a reference containing
ligand at the same total concentration Lt, the measured
absorbance becomes
A~eSbStzDe11bS L ½  ð 4Þ
Combining equation (4) with the stability constant definition
K11=[SL]/[S][L], gives
DA~K11De11bS ½  L ½  ð 5Þ
where DA=A2Ao. From the mass balance expression
St=[S]+[SL] we get [S]=St/(1+K11[L]), which is equation (5),
giving equation (6) at the relationship between the observed
absorbance change per centimeter and the system variables and
parameters.
DA
b
~
StK11De11 L ½ 
1zK11 L ½ 
ð6Þ
Equation (6) is the binding isotherm, which shows the hyperbolic
dependence on free ligand concentration.
The double-reciprocal form of plotting the rectangular
hyperbola
1
y
~
f
d
:1
x
z
e
d
, is based on the linearization of equation
(6) according to the following equation,
b
DA
~
1
StK11De11 L ½ 
z
1
StDe11
ð7Þ
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the binding constant can be estimated from the following equation
K11~
intercept
slope
ð8Þ
Molecular modeling
The PAMAM-G4 and polyphenols structures were generated
using the ChemOffice Ultra 6.0 software suite. The polyphenol
were then automatically docked to the rough PAMAM-G4
structure using ArgusLab 4.0.1 (ArgusLab 4.0.1, Mark A.
Thompson, Planaria SoftwareLLC, Seattle,WA, http://www.
arguslab.com). The docked polyphenol-PAMAM-G4 structures
were optimized by means of molecular dynamics using the MM+
force field available in HyperChem Pro 7.0. The heat time and
run time for the simulations were 2 ps and 28 ps respectively with
a step size of 0.001 ps. The temperature was initially set at 1 K
and gradually increased to 300 K during the heat time by
increments of 30 K. In all the simulations, equilibrium (achieving
constant temperature near the selected final value) was reached
after at most 20 ps. The free binding energies of the optimized
PAMAM-G4. Polyphenol complex structures were calculated
using the Ascore scoring function provided in the ArgusLab
software.
Results
FTIR Spectral analysis of drug-dendrimers
The infrared spectral features regarding drug-dendrimer
complexes are presented in Figures 2, 3, 4, 5, 6 and will be
discussed for each drug-polymer separately.
In Figure 2, the infrared spectra and difference spectra of
dendrimer complexes with resveratrol, are shown. Spectral shifting
Figure 2. FTIR spectra and difference spectra (diff.) in the region of 1800-600 cm
21 of hydrated films (pH 7.4) for free mPEG-
PAMAM-G3 (A), mPEG-PAMAM-G4 (B) PAMAM-G4 (C) (0.5 mM) and their resveratrol complexes obtained at different polyphenol
concentrations (indicated on the figure).
doi:10.1371/journal.pone.0033102.g002
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NH bending modes [30,31], due to drug hydrophilic interactions
with polymer polar groups. The major infrared bands at 1631
(C=O stretch and NH bending), 1556 (C-N stretch), 1405, 1299
(C-O), 1118, 1061 and 1039 cm
21 (C-O and C-C stretch), in the
infrared spectra of the free mPEG-PAMAM-G3 exhibited shifting
and intensity increases in the spectra of resveratrol-mPEG-
PAMAM-G3 complexes (Fig. 2A). Similarly, the major infrared
bands of the free mPEG-PAMAM-G4 at 1650, 1558, 1469, 1359,
1285, 1114 and 1062 cm
21 showed shifting and intensity changes,
upon resveratrol complexation (Fig. 2B). The infrared bands of the
free PAMAM-G4 at 1650, 1558, 1471, 1380, 1159 and
1060 cm
21 were also shifted, upon resveratrol interaction
(Fig. 2C). The observed spectral shifting was accompanied with
gradual increase in intensity of the above vibrational frequencies in
the difference spectra [(dendrimer+pigment solution) – (dendrimer
solution)] of drug-polymer complexes (Fig. 2A, 2B and 2C, diffs).
The spectral changes observed are attributed to the hydrophilic
interactions of drug OH groups with dendrimer NH2, C-O and C-
N groups. The hydrophilic interaction is more pronounced at high
resveratrol concentrations as it evidenced by increase in the
intensity of several positive features centered at 1650-1000 cm
21
in the different spectra of resveratrol-dendrimer complexes
(Fig. 2A, 2B and 2C, compare diffs 0.125 and 0.5 mM).
Genistein-polymer complexation induced major spectral chang-
es of the dendrimer infrared vibrational frequencies (Fig. 3). The
spectral changes was observed mainly for the C=O, C-N, C-O
stretching and NH bending modes [30,31] in the region of 1650-
1000 cm
21 of the infrared spectra of mPEG-PAMAM-G3,
mPEG-PAMAM-G4 and PAMAM-G4, upon genistein complex
formation (Fig. 3A, 3B and 3C). The spectral shifting was
associated with increase of intensity of these vibrations observed
in the difference spectra of genistein-dendrimer complexes
(Fig. 3A, 3B and 3C, diffs). More perturbations of polymers
spectra occurred at high genistein concentration (Fig. 3A, 3B and
3C, compare diffs of 0.125 mM and 0.50 mM). The observed
spectral changes are attributed to the hydrophilic contacts of drug
OH groups with dendrimer NH2, C-O and C-N groups.
Figure 3. FTIR spectra and difference spectra (diff.) in the region of 1800-600 cm
21 of hydrated films (pH 7.4) for free mPEG-
PAMAM-G3 (A), mPEG-PAMAM-G4 (B) PAMAM-G4 (C) (0.5 mM) and their genisteinl complexes obtained at different polyphenol
concentrations (indicated on the figure).
doi:10.1371/journal.pone.0033102.g003
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changes than other polyphenol-polymer complexes (Fig. 4).
Evidence for this comes from major shifting and intensity
variations of the dendrimer in-plan vibrations (Fig. 4A, 4B and
4C). The major intensity increases occurred at high curcumin
concentrations (Fig. 4A, 4B and 4C, compare diffs 0.125 mM and
0.50 mM). The observed spectral changes (shifting and intensity
increases) are due to a major curcumin-polymer complexation via
dendriemr C-O, C-N and NH2 groups with the polyphenol OH
groups. The stronger curcumin-polymer interaction is due to the
presence of several isomeric forms in solution (will be discussed
furtheron), which enhances polyphenol-dendrimer complexation.
The infrared spectra of cis-platin-dendriemr complexes shown
in Fig. 5 show cisplatin as a hydrophilic drug binds dendrimers via
Pt cation and the polymer terminal NH2 groups. Evidence for this
comes from major shifting of the polymer NH2 deformation mode
at 1631 (mPEG-PAMAM-G3), 1650 (mPEG-PAMAM-G4) and
1650 cm
21 (PAMAM-G4) to 1645 (cis-Pt-mPEG-PAMAM-G3),
1645 (cisPt-mPEG-PAMAM-G4) and 1644 cm
21 (cisPt-PAMAM-
G4) upon Pt complexation (Fig. 5A, 5B and 5C). The shifting of
the NH2 bending mode was accompanied by a major shifting of
the polymer NH stretching vibration at about 3280 cm
21 (will
be discusses in hydrophobic interactions furtheron) upon Pt
interaction.
Hydrophobic interactions
The effect of drug-dendrimer complexation on the polymer
antisymmetric and symmetric CH2 stretching vibrations in the
region of 3000-2800 cm
21 was investigated by infrared spectros-
copy [30,31]. The antisymmetric and symmetric CH2 bands of the
free mPEG-PAMAM-G3 located at 2944, 2884 and 2818 cm
21
were observed at 2944, 2984 and 2813 cm
21 (res-mPEG-
PAMAM-G3) at 2943, 2982 and 2814 cm
21 (gen-mPEG-
PAMAM-G3); at 2941, 2984 and 2813 cm
21 (cur-mPEG-
PAMAM-G3); at 2943, 2984 and 2817 cm
21 (cisPt-mPEG-
PAMAM-G3) (Fig. 6A). The antisymmetric and symmetric CH2
Figure 4. FTIR spectra and difference spectra (diff.) in the region of 1800-600 cm
21 of hydrated films (pH 7.4) for free mPEG-
PAMAM-G3 (A), mPEG-PAMAM-G4 (B) PAMAM-G4 (C) (0.5 mM) and their curcumin complexes obtained at different polyphenol
concentrations (indicated on the figure).
doi:10.1371/journal.pone.0033102.g004
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2817 cm
21 were at 2942, 2983 and 2807 cm
21 (res-mPEG-
PAMAM-G4); at 2943, 2982 and 2811 cm
21 (gen-mPEG-
PAMAM-G4); at 2941, 2983 and 2812 cm
21 (cur-mPEG-
PAMAM-G4); at 2944, 2984 and 2857 cm
21 (cisPt-mPEG-
PAMAM-G4) (Fig. 6B). The CH2 stretching vibrations of the free
PAMAM-G4, were at 2941 and 2837 cm
21 and shifted at 2932
and 2832 cm
21 (res-PAMAM-G4); at 2942 and 2934 cm
21 (gen-
PAMAM-G4); at 2942 and 2833 cm
21 (cur-PAMAM-G4) and at
2944 and 2837 cm
21 (cisPt-PAMAM-G4) (Fig. 6C). The shifting
of the dendrimer CH2 stretching vibrations was more pronounced
for resveratrol, genistein and curcumin than for cis-platin-
dendrimers (Fig. 6A, 6B and 6C). The observed spectral shifting
for polymer CH2 vibrations is indicative of major hydrophobic
interactions for resveratrol, genisten and curcumin with respect to
cisPt-dendrimers. This is due to the major hydrophobic parts
associated with pigment structure in comparison with inorganic
cisplatin drug. However, cisplatin-polymer binding is mainly
through hydrophilic interaction of Pt cation with dendrimer NH2
groups. Additional evidence for this come from major spectral
shifting of the polymer NH stretching vibrations at 3283 (mPEG-
PAMAM-G3), 3290 (mPEG-PAMAM-G4) and 3281 cm
21 (PA-
MAM-G4) towards a lower frequency at 3256 (cisPt-mPEG-
PAMAM-G3), 3270 (cisPt-mPEG-PAMAM-G4) and 3271 cm
21
(cisPt-PAMAM-G4) (Fig. 6A, 6B and 6C). The larger shifting
(Du=27-10 cm
21) observed for polymer NH stretching vibration,
is due to a major ionic interaction of polymer NH2 groups with Pt
cation in comparison with the polyphenol-dendrimer complexes
showing more hydrophobic interactions with minor perturbations
of polymer NH stretching vibrations.
UV-Visible spectra and stability of drug-dendrimers
The UV spectra of pigment-dendriemrs are presented in
Figures 7 (resveratrol and genistein) and 8 (curcumin and cis-
platin). It is clearly shown that as drug complexation occurs,
major intensity increase of the dendrimer UV band centered at
Figure 5. FTIR spectra and difference spectra (diff.) in the region of 1800-600 cm
21 of hydrated films (pH 7.4) for free mPEG-
PAMAM-G3 (A), mPEG-PAMAM-G4 (B) PAMAM-G4 (C) (0.5 mM) and their cis-platin complexes obtained at different drug
concentrations (indicated on the figure).
doi:10.1371/journal.pone.0033102.g005
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drug complex formation [32]. The spectral changes are more
pronounced in the case of resveratrol, genistein, cisplatin than
those of curcumin-dendrimers (Figs. 7 and 8). Curcumin with
enolic form in solid state forms several isomeric species in
solution (ketonic forms) with different affinities toward polymer
complexation [33,34]. Curcumin tends to form polymeric
complexes with dendrimers and this can explain the differences
in the UV spectral changes upon drug-polymer interactions
(Figs. 7 and 8).
The drug-dendrimer binding constants obtained (according to
the method described in experimental section) show one binding
constant for each drug-polymer complex (Figs. 7 and 8 and
Table 1). The affinity of dendrimer binding was PAMAM-
G4.mPEG-PAMAM-G4.mPEG-PAMAM-G3, while the order
of drug-polymer stability was curcumin.cisplatin.genistein.
resveratrol (Table 1). The bigger affinity of PAMAM-G4 over
mPEG-PAMAM-G3 and mPEG-PAMAM-G4 is due to the
presence of 64 amino groups on the periphery of the dendrimer
compared with 16 on mPEG-PAMAM-G4 and 8 on mPEG-
PAMAM-G3 dendrimers.
Docking study
Our results from FTIR and UV-visible spectroscopic methods
were complemented with molecular dynamic simulations in
which the resveratrol, genistein and curcumin were automatically
docked to PAMAM-G4 and the resulting structure was optimized
using the MM+ force field to determine the preferred
Figure 6. FTIR spectra in the region of 3300-2800 cm
21 of hydrated films (pH 7.4) for free mPEG-PAMAM-G3 (A), mPEG-PAMAM-G4
(B) and PAMAM-G4 (C) and their resveratrol. genistein, curcumin and cisplatin complexes obtained with 0.5 mM polymer and
pigment concentrations.
doi:10.1371/journal.pone.0033102.g006
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tion results are shown in Fig. 9 and Table 2. The models showed
that polyphenols are located in the cavities of PAMAM-G4 binding
polymer in a hydrophobic fashion (Fig. 9). The free binding energy
showed the order of binding genistein.curcumin.resveratrol
(Table 2). This is due to a more hydrophobic nature of genistein
in comparison with curcumin and resveratrol (Fig. 1). The dynamic
process of drug-dendrimer binding is shown in 3 videos for
curcumin-PAMAM-G4 (Video S1), for genistein-PAMAM-G4
(Video S2) and for resveratrol-PAMAM-G4 (Video S3).
Discussion
In constant search for designing tools to deliver drug in vivo,
variety of synthetic polymers have been tested and used [35]. An
ideal drug carrier must be biochemically inert and non-toxic, while
protecting drug until it reaches the target molecule and releasing the
drug. Among polymers, dendrimers are unique synthetic macromol-
ecules of nanometer dimensions with highly branched structure and
globular shape capable of transporting DNA, RNA and drug with
high efficiency [4,6]. These macromolecules have uniform size and
are mono-dispersed with modifiable surface functionality as well as
internal cavities. They contain several binding sites for hydrophobic,
hydrophilic, cationic and anionic drugs (Fig. 1). Dendrimers can be
used as a container which encapsulate drug molecules and carry to
different targets in vivo [9,36–38]. It has been shown that dendrimers
with a hydrophobic interior and hydrophilic chain ends are able to
solubilize hydrophobic compounds in aqueous solutions [38,39].
Attempts have been made to design different dendrimers as drug
carriers [9]. For example, anticancer fluorouracil drug was attached
to the dendrimers with cyclic core [10] or using dendrimers having
poly(ethylene glycol) grafts to encapsulate antitumor drugs adriamy-
cin and methotrexate [11]. The complexation of dendrimers with
anti-inflammatrory drug flurbiprofen was studied in vitro and in vivo,
while drug biodistribution in different organs has been monitored
[40]. Gene delivery targeted to brain has been attempted using
transferring-conjugated polyethyleneglycol-modified polyamidoa-
mine dendrimer [41]. The purpose of our investigation was to
evaluate the potential of dendrimers as nanoscale drug delivery tools
to carry hydrophilic (cisplatin) and hydrophobic drugs (resveratrol,
genistein and curcumin). Resveratrol and genistein) with three OH
groups and two and three phenolic rings, respectively are mainly
Figure 7. UV-visible spectra of mPEG-PAMAM-G3, mPEG-PAMAM-G4 and PAMAM-G4 and their complexes with resveratrol and
genistein with free dendrimer at 100 mM and complexes b-I at 20 to 130 mM. (A, B and C) Resveratrol with mPEG-PAMAM-G3,
mPEG-PAMAM-G4 and PAMAM-G4 respectively. (D, E and F) Genistein with mPEG-PAMAM-G3, mPEG-PAMAM-G4 and PAMAM-G4
respectively. (A9, B9 and C9) Plots of 1/(A-A0) vs (1/pigment concentration) and binding constant (K) for Res-mPEG-PAMAM-G3, Res-mPEG-PAMA-G4,
and Res-PAMAM-G4 respectively. (D9, E9 and F9) Plots of 1/(A-A0) vs (1/pigment concentration) and binding constant (K) for Gen-mPEG-PAMAM-G3,
Gen-mPEG-PAMA-G4, and Gen-PAMAM-G4 respectively.
doi:10.1371/journal.pone.0033102.g007
Dendrimer-Drug Interaction
PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e33102hydrophobic in character and not soluble in water (Fig. 1). Curcumin
in its keto form with two OH, two C=O and two methoxy groups
also shows hydrophobic character, while soluble in ethanolic solution
(Fig. 1). However, cisplatin drug is an example of hydrophilic drug
soluble in water.
Infrared spectroscopic data in the region of 1700-1000 cm
21,
where most of the polymer in-plane vibrations related to C=O, C-N,
NH and C-O modes are located exhibited spectral changes (shifting
and intensity variations) upon drug-polymer complexation. These
changes were more profound in the caseof cisplatin drug with respect
to resveratrol, genistein and curcumin-dendrimer complexes. It
showed clearly that the more hydrophilic drug induced more
perturbations of polymer hydrophilic group vibrational frequencies
with the order of spectral changes cisplatin.genistein.curcumin.
resveratrol (Figs. 2, 3, 4, 5). This can be expected since cisplatin drug
is the most hydrophilic with genistein being more hydrophilic than
curcumin and resveratrol. However, analyses of the polymer CH2
stretching region (2900-2800 cm
21) exhibited shifting of the bands
due to the polyphenol-polymer complexation (Fig. 6). The order of
spectral shifting was resveratrol.genistein.curcumin.cispltin indi-
cating little hydrophobic interaction for cisplatin-polymer complexes
(Fig.6).However,considerableshifting of theNHstretching vibration
at about 3280 cm
21 toward a lower frequency was observed in the
sperctra of cisplatin-dendrimers indicating a major hydrophilic
Figure 8. UV-visible spectra of mPEG-PAMAM-G3, mPEG-PAMAM-G4 and PAMAM-G4 and their complexes with curcumin and
cisplatin with free dendrimer at 100 mM and complexes b-I at 20 to 130 mM. (A, B and C) Curcumin with mPEG-PAMAM-G3, mPEG-
PAMAM-G4 and PAMAM-G4 respectively. (D, E and F). Cisplatin with mPEG-PAMAM-G3, mPEG-PAMAM-G4 and PAMAM-G4 respectively. (A9, B9
and C9) Plots of 1/(A-A0) vs (1/pigment concentration) and binding constant (K) for Cur-mPEG-PAMAM-G3, Cur-mPEG-PAMA-G4, and Cur-PAMAM-G4
respectively. (D9, E9 and F9) Plots of 1/(A-A0) vs (1/pigment concentration) and binding constant (K) for cis-mPEG-PAMAM-G3, cis-mPEG-PAMA-G4,
and cis-PAMAM-G4 respectively.
doi:10.1371/journal.pone.0033102.g008
Table 1. Calculated binding constants (K) for drug-dendrimer complexes.
DENDRIMERS Curcumin (K) Genistein (K) Resveratrol (K) Cis-platin (K)
mPEG–G3 1.8 (60.5)610
3 M
21 1.3 (60.3)610
3 M
21 3.0 (60.7)610
2 M
21 1.7 (60.3)610
3 M
21
mPEG–G4 4.1 (60.9)610
3 M
21 3.7 (60.6)610
3 M
21 1.0 (60.2)610
3 M
21 3.0 (60.7)610
3 M
21
PAMAM-G4 8.3 (±0.9)610
3 M
21 4.1 (±0.6)610
3 M
21 5.9 (±0.7)610
3 M
21 7.9 (60.8)610
3 M
21
doi:10.1371/journal.pone.0033102.t001
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The order of hydrophilic interaction was cisplatin.genistein.
curcumin.resveratrol.
The stability of drug-polymer complexes varies as dendrimer
composition changes. PAMAM-G4 with 64 terminal amino groups
forms more stable complexes than those of mPEG-PAMAM-G4
with 16 terminal NH2 groups and mPEG-PAMAM-G3 with 8
amino groups (Table 1). Drug with both hydrophilic and
hydrophobic affinities such as curcumin forms stronger complexes
than cisplatin, genistein and resveratrol with the order of stability
curcumin.cisplatin.genistein.resveratrol (Table 1).
Molecular modeling showed polyphenol interaction with the
hydrophobic parts of dendrimer with genistein-PAMAM more
stable than resveratrol and curcumin-polymer complexes due to a
more hydrophobic nature of genistein.
Conclusion
In summary, based on our spectroscopic and docking results
dendrimers are capable of binding to both hydrophilic and
Figure 9. Optimized polyphenol-PAMAM-G4 docking structures. The polyphenols are shown in green color. (A) shows whole PAMAM-G4 in
spheres with resveratrol and (A9) shows the zoom on the binding site represented in sticks. (B) shows whole PAMAM-G4 in spheres with genistein
and (B9) shows the binding site represented in sticks. (C) whole PAMAM-G4 in spheres with curcumin and (C9) shows the binding site in represented
in sticks.
doi:10.1371/journal.pone.0033102.g009
Table 2. Binding energy for the best docking positions for
drug-dendrimer Complexes.
Complex DGbinding (kcal/mol)
Resveratrol – PAMAM-G4 24.39
Genistein – PAMAM-G4 24.75
Curcumin – PAMAM-G4 24.53
doi:10.1371/journal.pone.0033102.t002
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cavities. The low binding constants of pigment-polymers 10
2 to
10
3 M
21 indicate a weak complexation and an easy dissociation
of drug molecule from dendrimer complexes, which is essential
for suitable delivery systems. Hydrophobic drugs such as
resveratrol, genistein and curcumin are mainly bound to internal
cavities with some degree of hydrophilic contact via pigment OH
groups, while hydrophilic cisplatin drug bind mainly via
hydrophilic contacts with terminal NH2 groups. However,
dendrimers with more internal cavities are effective carriers for
hydrophobic drugs. This study clearly showed the applications of
spectroscopic and docking techniques in structural analysis of
dendrimer complexes with hydrophilic and hydrophobic drugs
that are of major importance in designing and developing
efficient tool in drug delivery systems.
Supporting Information
Video S1 The dynamic process of drug-dendrimer
binding is shown in a video for curcumin-PAMAM-G4.
(AVI)
Video S2 The dynamic process of drug-dendrimer
binding is shown in a video for genistein-PAMAM-G4.
(AVI)
Video S3 The dynamic process of drug-dendrimer
binding is shown in a video for resveratrol-PAMAM-G4.
(AVI)
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